ArticleEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery2025
The Evolving Risk of Infective Endocarditis After Transcatheter Aortic Valve Implantation.
Article in European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging insights into infective endocarditis in the era of transcatheter aortic valve implantation.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectivesDespite increased use of transcatheter aortic valve implantation (TAVI) in older adults with severe aortic stenosis, contemporary data on infective endocarditis (IE)-an infrequent but serious complication-are lacking. This study addresses this gap in knowledge.
methodsWe analysed 280 073 Medicare beneficiaries who underwent TAVI between 2013 and 2022. The primary outcome was the change in the 1-year incidence rate of IE post-TAVI. Joinpoint regression was used to evaluate the trend in the IE incidence as annual percent change (APC). Adjusted Cox models were used to evaluate associations between IE incidence and patient characteristics, as well as 12-month outcomes.
resultsThe incidence rate of IE 1 year post-TAVI decreased from 20.0/1000 person-years in 2013 to 13.1/1000 in 2021. There was no change in incidence between 2013 and 2018 but a significant decline thereafter (-12.1% [CI, -20.7% to -7.5%], P < .001). This decline was associated with the decrease in non-elective TAVI (sub-distribution hazard ratio: 0.98 [CI, 0.94-0.99], P < .001); 4.8% of patients with IE underwent aortic valve reintervention. The 30-day aortic valve reintervention rate after IE increased significantly from 2013 to 2022 (APC: 24.9% [CI, 17.2%-33.0%], P < .001). The 30-day mortality rate after TAVI explant was 9.3%; the adjusted risk of death declined over time (HR: 0.73 [CI, 0.58-0.92], P = .01). However, the overall 30-day risk-adjusted mortality rate of TAVI-IE remained unchanged.
conclusionsThe post-TAVI incidence of IE in Medicare patients decreased after 2019. This decrease was associated with declining rates of non-elective TAVI and coincided with FDA approval of TAVI for low-risk patients. TAVI explant rates were low but increased recently. The lack of improvement in 30-day mortality underscores the challenges of elderly care after TAVI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.